Can someone tell me what the primary endpoint was that they missed. I was told that they were short by 1 or 2 clinical trials? I was also told that the product does work and it will be FDA approved shortly. If this is true, the stock will go back over $2 quickly then continue to rise for a long time.
News 
Market Data 
Discover 
